newsfilter
← Latest News
GlobeNewswire·

Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy

• AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding...